U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H22N2O2S
Molecular Weight 330.444
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXOMEMAZINE

SMILES

CC(CN(C)C)CN1C2=CC=CC=C2S(=O)(=O)C3=CC=CC=C13

InChI

InChIKey=QTQPVLDZQVPLGV-UHFFFAOYSA-N
InChI=1S/C18H22N2O2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3

HIDE SMILES / InChI
Molecular Formula C18H22N2O2S
Molecular Weight 330.444
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Oxomemazine is a histamine H₁-receptor antagonist. Additionally, oxomemazine could be classified as a ligand for M1 receptors. It is used in the symptomatic treatment of non-productive coughs that occur specifically at night.

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
[Comparative study of two antitussive drugs in the treatment of acute dry cough of infectious origin (prospective, randomized, single blind study)].
2002 Sep-Oct
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec

Sample Use Guides

In Vivo Use Guide
Oxomemazine 0.33 mg/ml syrup. Suitable for adults and children over 40 kg (from the age of 12 years old). 10 ml 4 times per day. For children: The daily dose according to a child’s weight (1ml of syrup per kg per day): · Child between 13-20 kg (between 2-6 years old): 5ml 2-3 times per day. · Child between 20-30 kg (between 6-10 years old): 10 ml 2-3 times per day. · Child between 30-40 kg (between 10-12 years old): 10 ml 3-4 times a day. Repeat if necessary minimum every 4 hours. Due to the sedative effect of oxomemazine it is advisable to take this medication in the evening.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:45:36 GMT 2023
Edited
by admin
on Sat Dec 16 16:45:36 GMT 2023
Record UNII
305MB38V1C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXOMEMAZINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
EXE-TOP
Brand Name English
oxomemazine [INN]
Common Name English
OXOMEMAZINE [MART.]
Common Name English
DOXERGAN
Brand Name English
IMAKOL
Brand Name English
10-(3-(DIMETHYLAMINO)-2-METHYLPROPYL)PHENOTHIAZINE 5,5-DIOXIDE
Systematic Name English
OPLEX
Brand Name English
DYSEDON
Brand Name English
Oxomemazine [WHO-DD]
Common Name English
PHENOTHIAZINE, 10-(3-(DIMETHYLAMINO)-2-METHYLPROPYL)-, 5,5-DIOXIDE
Systematic Name English
OXOMEMAZINE [MI]
Common Name English
6847-RP
Code English
6487-RP
Code English
TRIMEPRAZINE 5,5-DIOXIDE
Common Name English
RP-6847
Code English
RP 6847
Code English
10H-PHENOTHIAZINE-10-PROPANAMINE, N,N,.BETA.-TRIMETHYL-, 5,5-DIOXIDE
Systematic Name English
(±)-OXOMEMAZINE
Common Name English
Classification Tree Code System Code
WHO-ATC R06AD08
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
NCI_THESAURUS C29704
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
WHO-VATC QR06AD08
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
Code System Code Type Description
INN
1412
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
DRUG BANK
DB13820
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
NCI_THESAURUS
C73008
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
ECHA (EC/EINECS)
222-996-8
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
FDA UNII
305MB38V1C
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
MESH
C119593
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
DRUG CENTRAL
2025
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
SMS_ID
100000083073
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104734
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
WIKIPEDIA
Oxomemazine
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
EVMPD
SUB09549MIG
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
CAS
156576-01-1
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
SUPERSEDED
MERCK INDEX
m8315
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID5023405
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
CAS
3689-50-7
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
PUBCHEM
19396
Created by admin on Sat Dec 16 16:45:36 GMT 2023 , Edited by admin on Sat Dec 16 16:45:36 GMT 2023
PRIMARY
Related Record Type Details
Structure of OXOMEMAZINE, (-)-
ENANTIOMER -> RACEMATE
Structure of OXOMEMAZINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of OXOMEMAZINE, (+)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of OXOMEMAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966